Dvir Thal Levin, MSc | Founder @ CANNFIELD đż | Medical cannabis operator | Speaker | Genetics & global cannabis markets
Joined November 2020
- Tweets 3,346
- Following 1,061
- Followers 298
- Likes 473
1,171 Photos and videos
Most people see a cannabis plant.
I see terpene architecture. Cannabinoid ratios. The gap between whatâs on a COA and what actually reaches the patient.
25 years of knowing exactly what to look for.
Thatâs the difference between medicine and a commodity.
CANNFIELD International
6
Everyone asked me why I left everything behind to build a cannabis company.
Because Iâve seen what it does to a 78-year-old veteran who hasnât slept in 11 years.
I donât sell cannabis.
I give people their lives back.
Thatâs not a business plan.
Thatâs a belief system.
1
17
Pharmaceutical quality isnât a feature. Itâs the foundation.
In 2026, the winners in medical cannabis wonât be those with the lowest price, but those with the highest standards.
From GACP to EU-GMP quality comes first.
20
This is where medicine starts.
Not in labs. In genetics.
Quality control. Precision. Standards.
The difference between medicine and consumer product is one decision.
16
Some men chase trends. Others study the plant that rewired modern medicine and build empires from it. đż
22
Full PPE. Peak flowering. GMP-certified facility.
This is what pharmaceutical-grade cannabis due diligence actually looks like on-site, not on paper.
CANNFIELD has been doing this for 10 years across Israel, Germany, Canada & LATAM.
Quality is a process. Not a certificate.
35
Cannabis education is the biggest market nobodyâs building.
Doctors donât know it. Patients donât understand it. Investors ignore it.
The first person to own cannabis education owns the industry.
8
The cannabis industry will be defined by one choice:
Optimize for profit or optimize for outcomes.
Most choose profit. Theyâll be dead in 5 years.
The ones who choose outcomes will own the future.
Which side are you building?
6
Most cannabis companies donât fail in Germany because of product.
They fail because of execution.
Germany isnât a cannabis market itâs a pharma-grade system.
While others chase trends, CANNFIELD INTERNATIONAL is building long-term infrastructure, genetics, and EU partnerships.
18
âMedical cannabis is widely discussed but poorly understood.
A lot of whatâs called âmedical progressâ is still ahead of solid evidence.
Weâre not in a phase of certainty. Weâre in a phase of learning.
And confusing the two always costs industries later.â
8
This leaf represents precision. Not recreation.
Every variable controlled. Every plant monitored. Every outcome measured.
This is medical cannabis. Not a trend. A science.
The ones who understand the difference will lead the next decade.
18
Today I unveiled CANNFIELDâs mission: real rehabilitation for combat veterans with PTSD.
Not symptom management. Recovery.
Weâre raising partners clinics, organizations, investors who believe medicine should heal, not just mask.
If youâre in, letâs build it.
5
Speaking to the next generation of doctors about what medical schools wonât teach them.
Cannabis. PTSD. Combat trauma. Real outcomes.
The gap between science and education is where real change happens.
3
×× × ×¤××Ą× ××ר×××:
This is precision farming. Not a hobby.
Every plant monitored. Every variable controlled. Every outcome measured.
This is how you build medicine, not just product.
The difference between a grower and a scientist is one decision.
14
×ר×׊××:
Everyone wants to be a cannabis entrepreneur.
Nobody wants to be a cannabis scientist.
Thatâs why the industry is broken.
Money flows to growers and retailers. Knowledge stays in universities.
7
Your doctor wonât prescribe cannabis because their medical school didnât teach it.
Your insurance wonât cover it because pharma blocked it.
So you suffer.
And everyone profits from your silence except you.
That changes when you demand better.
8
The cannabis industry will collapse in 5 years.
Not because of regulation. Because most companies built on sand.
No clinical data. No real distribution. No moat.
Only the ones who invested in infrastructure will survive.
Build systems, not just products.
7
Iâm not here to sell cannabis. Iâm here to build the infrastructure that turns it into medicine.
Most companies focus on the plant. I focus on the system.
Regulatory frameworks. Clinical data. Global standards.
Thatâs where the real value is.
16
Speaking about Germanyâs cannabis market to international investors.
While most companies chase trends, we build frameworks.
Thatâs the difference between a business and a legacy.
16
Medical cannabis isnât failing because of regulation.
Itâs failing because doctors donât understand it.
Every day a patient self-medicates because their doctor wonât prescribe.
Thatâs the tragedy.
13